Paragon Bioservices Wins CMO Leadership Awards

Life Science Leader Magazine Recognizes Paragon Six Years in a Rows

BALTIMORE, March 14, 2017/PRNewswire/— Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today that it has received CMO Leadership Awards for 2017. Paragon received the awards in all six of the core categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.

“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”

Paragon functions as a translational bridge—from the research bench through manufacturing of finished drug product for Phase I/II clinical trials. Paragon’s aim is to build strong development and manufacturing partnerships with biopharmaceutical clients, focusing on transformative technologies, including oncology immunotherapies (CAR‐T cell therapies and oncolytic viruses), new generation vaccines (VLPs) and gene therapies (AAV).

“Industry Standard Research is honored to conduct the research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s research to make confident business decisions based on the experiences of their industry peers.”

Peter Buzy, CEO of Paragon Bioservices,”Credit for this recognition goes to all of our hard-working scientists, engineers, quality systems personnel and project managers. This acknowledgement from our peers is a great honor and we hope that it reflects our dedication and passion for the science.  At Paragon, we are committed to build a world class GMP organization to support our growth initiatives in vaccine and gene-therapy viral vector manufacturing.”

About Paragon Bioservices, Inc.
Paragon Bioservices is a private‐equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing.  Paragon’s cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.

Media Contact
Philip Wills, VP Business Development & Principal Scientist
PH (410) 975‐4056